The REVITALYZ study met its primary endpoint, demonstrating significant improvements in excessive daytime sleepiness for adults with idiopathic hypersomnia treated with once-nightly LUMRYZ.
Drug candidates aim to address the root cause of narcolepsy type 1—orexin deficiency—with some also being explored for narcolepsy type 2 and idiopathic hypersomnia.
Harmony reveals new data showing pitolisant's safety at five times the highest labeled dose of WAKIX, along with updates on its orexin-2 agonist and long-term efficacy of pitolisant in IH.
Bruce Cozadd, co-founder, chairperson, and CEO of Jazz, announced plans to retire as CEO upon the appointment of a successor by the end of 2025.
Read More
The Illuminate Hypersomnia Adjunct Scientific Meeting on Feb 13, 2025, will address challenges in idiopathic hypersomnia drug development.
Read More
A global survey reveals that peer connections significantly improve support and adjustment for individuals with narcolepsy and idiopathic hypersomnia.
Read More
Centessa Pharmaceuticals has initiated a phase 2 trial of ORX750, an oral orexin receptor 2 agonist designed to treat narcolepsy type 1, type 2, and idiopathic hypersomnia.
Read More
Centessa Pharmaceuticals discontinues SerpinPC, an investigational hemophilia B therapy, to reallocate resources to its orexin receptor program.
Read More
During the quarter, Lumryz saw increased patient uptake, expanded to pediatric use, and secured a legal victory affirming its clinical superiority, as the company continues its phase 3 trial in idiopathic hypersomnia.
Read More
Alkermes’ presentations feature research on its investigational treatment ALKS 2680 in narcolepsy and insights on the burden of living with the condition.
Read More
Jazz Pharmaceuticals reported record third-quarter 2024 revenues of over $1.05 billion, with strong performance from its sleep portfolio.
Read More
The companies will combine to focus on advancing NLS’ orexin platform and Kadimastem’s cell therapy program.
Read More
Top-line results show improvements on excessive daytime sleepiness and key polysomnography outcomes.
Read More
Wakix surpassed $2 billion in cumulative revenue since its 2019 launch for adult narcolepsy, with Harmony on track to submit a supplemental new drug application for idiopathic hypersomnia in Q4.
Read More
Alkermes’ Q3 update reveals progress for ALKS 2680, an orexin 2 receptor agonist aimed at treating narcolepsy and idiopathic hypersomnia, with phase 2 trial completions expected in 2025.
Read More
With increasing FDA clearances for standalone software in sleep medicine, “software as a medical device” is becoming a key term. Experts explain what SaMD entails and explore its unique advantages and challenges.
Read More
In non-human primate models, oral administration of ORX142 promoted sustained increases in wakefulness at the lowest dose tested.
Read More
Zevra’s Rene Braeckman, PhD, will present the top-line results from the phase 2 trial evaluating the safety and tolerability of KP1077 for idiopathic hypersomnia at Sleep Europe 2024.
Read More